These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6765062)

  • 41. Bromocriptine (ParlodelR) in the treatment of Parkinson's disease.
    Molina-Negro P; Grimes JD; Jones MW; Kofman OS; Bouchard S
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):503-8. PubMed ID: 6761765
    [No Abstract]   [Full Text] [Related]  

  • 42. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
    Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD
    Therapie; 1993; 48(3):233-8. PubMed ID: 7908147
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.
    Anglès A; Bagheri H; Saivin S; Montastruc JL
    Therapie; 2002; 57(4):408-10. PubMed ID: 12422563
    [No Abstract]   [Full Text] [Related]  

  • 44. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Use of bromocriptine in Parkinson diseases in low doses at a slow rate. 40 patients].
    Liaño H; López-Lozano JJ; Ramírez A; Rabes C; Pascual ML
    Arch Neurobiol (Madr); 1984; 47(3):143-50. PubMed ID: 6508478
    [No Abstract]   [Full Text] [Related]  

  • 46. Dystonia: treatment with bromocriptine.
    Newman RP; LeWitt PA; Shults C; Bruno G; Foster NL; Chase TN; Calne DB
    Clin Neuropharmacol; 1985; 8(4):328-33. PubMed ID: 3907823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multi-center, double-blind study on slow-release bromocriptine in the treatment of Parkinson's disease.
    Mannen T; Mizuno Y; Iwata M; Goto I; Kanazawa I; Kowa H; Nishitani H; Ogawa N; Takahashi A; Tashiro K
    Neurology; 1991 Oct; 41(10):1598-602. PubMed ID: 1922801
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapeutic effects of Nicholin (CDP-choline): Parkinson's syndrome.--a double-blind study].
    Tsubaki T; Kase M; Ando K; Manaka N; Sato Y
    Nihon Rinsho; 1974 Nov; 32(11):3435-50. PubMed ID: 4616105
    [No Abstract]   [Full Text] [Related]  

  • 49. A double-blind evaluation of lysivane in the treatment of Parkinson's disease.
    Strang RR
    Br J Clin Pract; 1966 May; 20(5):249-51. PubMed ID: 5326485
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical evaluation of biperiden in Parkinson's disease.
    Strang RR
    Dis Nerv Syst; 1967 Mar; 28(3):191-3. PubMed ID: 5335879
    [No Abstract]   [Full Text] [Related]  

  • 51. [Bromocriptine and Parkinson's disease].
    Vaskov Z; Milić V
    Vojnosanit Pregl; 1985; 42(2):134-7. PubMed ID: 4024502
    [No Abstract]   [Full Text] [Related]  

  • 52. A double-blind evaluation of S.D. 25 in the treatment of Parkinson's disease.
    Strang RR
    Curr Med Drugs; 1966 Dec; 7(4):20-6. PubMed ID: 5976205
    [No Abstract]   [Full Text] [Related]  

  • 53. Cognitive performances in parkinsonians before and after bromocriptine therapy.
    Piccirilli M; Piccinin GL; D'Alessandro P; Finali G; Piccolini C; Scarcella MG; Testa A
    Acta Neurol (Napoli); 1986 Jun; 8(3):167-72. PubMed ID: 3739763
    [No Abstract]   [Full Text] [Related]  

  • 54. Low-dose bromocriptine in Parkinson's disease.
    Pearce I; Pearce JM
    J Neurol Neurosurg Psychiatry; 1985 Apr; 48(4):388-9. PubMed ID: 3998746
    [No Abstract]   [Full Text] [Related]  

  • 55. [Bromocriptin in Parkinson's syndrome].
    Völler GW; Ulm G
    Med Welt; 1979 Dec; 30(51-52):1930-3. PubMed ID: 542110
    [No Abstract]   [Full Text] [Related]  

  • 56. Parkinson's disease and hypertension: chronic bromocriptine treatment.
    Montastruc JL; Chamontin B; Rascol A
    Neurology; 1985 Nov; 35(11):1644-7. PubMed ID: 4058753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Bromocriptine].
    Raphael V
    Soins Gynecol Obstet Pueric Pediatr; 1989 Nov; (102):I-II. PubMed ID: 2617395
    [No Abstract]   [Full Text] [Related]  

  • 58. Low dose bromocriptine ameliorates hallucinations in a demented parkinsonian patient.
    Sandyk R
    J Clin Psychopharmacol; 1987 Apr; 7(2):114-5. PubMed ID: 3584516
    [No Abstract]   [Full Text] [Related]  

  • 59. Bromocriptine induced impotence in Parkinson's disease.
    Cleeves L; Findley LJ
    Br Med J (Clin Res Ed); 1987 Aug; 295(6594):367-8. PubMed ID: 3115453
    [No Abstract]   [Full Text] [Related]  

  • 60. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine.
    Demonet JF; Rostin M; Dueymes JM; Ioualalen A; Montastruc JL; Rascol A
    Clin Neuropharmacol; 1986; 9(2):200-1. PubMed ID: 3708605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.